Compare Eli Lilly And Co (LLY) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Veritone Inc — how do they compare? Eli Lilly And Co trades at $1,220.01 (market cap $1.08T), while Veritone Inc trades at $1.54 (market cap $138.04M). The key difference: Eli Lilly And Co is far larger — about 7823.8× Veritone Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| LLY | VERI | |
|---|---|---|
Market Cap | $1.08T | $138.04M |
Sector | Health | Technology |
52-Week High | $1.24K | $8.39 |
52-Week Low | $639.43 | $1.00 |
Enterprise Value | $1.13T | $170.07M |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Veritone (VERI) trades at $1.53, up 6.25% in 24 hours, with a bullish technical signal from moving averages and ADX indicators. The company reported revenue of $92.19M in 2025 but a net loss of $111.73M, reflecting negative profit margins and ROE. Recent news highlights partnerships with ZeroEyes and the Department of Energy, though a securities class action lawsuit was filed in July 2026 over alleged accounting issues.
The outlook is mixed: analyst consensus leans neutral with 46% buy ratings, but persistent losses and legal risks pose challenges. Upside hinges on AI partnership growth improving profitability, while downside risks include ongoing cash burn and litigation uncertainties. Investors should weigh growth potential against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
